We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Drug delivery is about improving the efficacy and safety of therapeutics by getting the right dose of the right drug to the right place at the right rate and time.
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Several pharmaceutical and biotechnology companies in China are actively involved in the research and development of Central Nervous System (CNS) drugs.
AdvertisingEmail to: Julia.zhang@imsinoexpo.com
Media CooperationEmail to: Jennifer.Yang@imsinoexpo.com
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!